Plain-English translation of NCT06103916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing how well a diagnostic assessment tool called the ADNEX model works in real-world hospital settings to help doctors determine whether an ovarian tumor is benign or cancerous. Researchers will collect ultrasound data from women across Dutch hospitals over five years to see if this tool performs as accurately in everyday practice as it has in research settings.
While the ADNEX model has shown promise in research studies, doctors need to know how reliable it actually is when used in regular clinical practice. Dutch medical guidelines now recommend using this tool, so real-world performance data is essential to ensure it helps doctors make the best treatment decisions for their patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, your participation involves having your existing ultrasound data and medical information recorded in a research database. This is a non-invasive observational study — you will not receive any new treatment or undergo any additional procedures beyond standard care. Your data will be tracked as part of the study over five years to help researchers understand how well the diagnostic tool works across different Dutch hospitals.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Netherlands
Sponsor
Maxima Medical Center
Collaborators
Radboud University Medical Center, The Netherlands Cancer Institute
Enrollment target
~613 participants
Started
July 2022
Primary completion
August 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Esther Lems, MD
Maxima Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.